Stephens Inc. AR Boosts Stock Position in Repligen Corporation $RGEN

Stephens Inc. AR grew its holdings in Repligen Corporation (NASDAQ:RGEN) by 2.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,594 shares of the biotechnology company’s stock after buying an additional 1,359 shares during the quarter. Stephens Inc. AR owned 0.08% of Repligen worth $5,920,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Alliance Wealth Advisors LLC UT boosted its stake in shares of Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 89 shares during the last quarter. State of Michigan Retirement System boosted its stake in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $1,585,000 after acquiring an additional 100 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock worth $1,858,000 after acquiring an additional 100 shares during the last quarter. State of Wyoming boosted its stake in shares of Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 115 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RGEN. Stephens raised Repligen to an “overweight” rating and set a $160.00 price target on the stock in a research note on Tuesday, July 22nd. HSBC began coverage on Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target on the stock. Evercore ISI lifted their price target on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 30th. Finally, HC Wainwright reissued a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Stock Performance

NASDAQ RGEN opened at $156.75 on Wednesday. The stock’s fifty day moving average is $130.37 and its two-hundred day moving average is $126.83. The firm has a market capitalization of $8.82 billion, a P/E ratio of -626.97, a price-to-earnings-growth ratio of 3.42 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period last year, the firm posted $0.40 EPS. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.